EMA Recommends Extension of Therapeutic Indications for Cetuximab By Ogkologos - August 14, 2026 65 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of adult patients with BRAF V600E-mutated mCRC in combination with encorafenib Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with... August 26, 2022 Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft August 5, 2019 Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... November 17, 2022 What Survivors Should Know When Transitioning From Cancer Care to Primary... April 4, 2023 Load more HOT NEWS Giving Myself the Most Time and Best Chance at Beating Cancer:... AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading Intermittent Fasting New Drugs, New Side Effects: Complications of Cancer Immunotherapy
